FINANCIAL SERVICES

HCL Technologies

Estimate change	$ \longleftarrow $
TP change	
Rating change	

Bloomberg	HCLT IN
Equity Shares (m)	2714
M.Cap.(INRb)/(USDb)	5398.6 / 62.4
52-Week Range (INR)	2012 / 1235
1, 6, 12 Rel. Per (%)	8/33/24
12M Avg Val (INR M)	5182

Financials & Valuations (INR b)

Y/E Mar	FY25E	FY26E	FY27E
Sales	1,174	1,299	1,419
EBIT Margin (%)	18.2	18.9	18.8
PAT	174	198	219
EPS (INR)	63.8	72.7	80.7
EPS Gr. (%)	10.2	14.0	11.0
BV/Sh. (INR)	248	245	241
Ratios			
RoE (%)	25.6	29.6	33.2
RoCE (%)	22.8	26.6	29.5
Payout (%)	90.0	90.0	90.0
Valuations			
P/E (x)	31.2	27.3	24.6
P/BV (x)	8.0	8.1	8.3
EV/EBITDA (x)	21.0	18.2	16.7
Div Yield (%)	2.9	3.3	3.7

Shareholding pattern (%)

As On	Sep-24	Jun-24	Sep-23							
Promoter	60.8	60.8	60.8							
DII	15.8	15.8	15.7							
FII	18.9	18.7	19.0							
Others	4.5	4.7	4.5							
FII Includes dep	FII Includes depository receipts									

CMP: INR1,989 TP: INR2,400 (+21%) Guidance upgrade dampens enthusiasm

Buy

3Q organic revenues miss estimates, but CY25 outlook upbeat

HCL Technologies (HCLT) reported a revenue of USD3.5b, up 3.8% QoQ and 4.1% YoY in constant currency (CC), above our estimate of 3.7% QoQ CC growth (largely owing to one-month inorganic contribution from HPE CTG acquisition). EBIT margins came in at 19.5%, beating our estimate of 19.1%. New deal TCV stood at USD2.1b (down 5.5% QoQ) in 3QFY25. For FY25, the revenue growth guidance has been upgraded to 4.5%-5.0% YoY cc (including a ~50bp contribution from the HPE CTG acquisition, with organic growth at 4.0%-4.5%) from the earlier range of 3.5%-5.0%. For 4QFY25, the implied organic growth for ITB&S is now in the range of -1.6% to +0.6% QoQ in cc, which is a downgrade, in our view. For 9MFY25, revenue/EBIT/PAT grew 6.6%/6.5%/11.7% compared to 9MFY24. We expect revenue/EBIT/PAT to grow by 7.3%/6.6%/7.3% YoY in 4QFY25. We reiterate our BUY rating on HCLT with a TP of INR2,400, implying a 21% potential upside.

Our view: Implied 4Q growth for IT&BS soft

- HCLT's 3Q numbers and 4Q guidance were underwhelming. The implied organic growth rate for IT&BS in 4Q is approximately 0.6% in CC at the upper end of the guidance. Management attributed this to a planned ramp-down in the Verizon deal and some project completions. However, in an environment where short-cycle deals are gaining momentum, the slower ramp-up of discretionary deals in 4Q is a dampener.
- We previously argued HCLT should trade at a roughly 10% premium to Infosys (see our <u>1QFY25 HCLT RU - Steady now, strong ahead</u>). This was owing to its superior outperformance to its peers over the past 2-3 years, with improving capital allocation and free cash flow metrics.
- Valuation parity is now achieved for the big three—HCLT, TCS, and Infosys. The hurdle rate for HCLT to now re-rate is higher than its peers.
- Nonetheless, we believe HCLT's diversified portfolio is well-positioned. Often perceived as defensive, its strengths in data, product engineering, and modernization should enable it to benefit from the recovering demand environment.
- More importantly, a 23% increase in ACV (which HCLT started reporting this quarter) despite a muted TCV bodes well for short-cycle deals and should continue to benefit HCLT in the medium term.

Valuations and changes in estimates

We expect HCLT to deliver 18.2% EBIT margin in FY25, which should recover to 18.9% in FY26 as growth improves. We expect HCLT to deliver a CAGR of 7.5%/11.7% in USD revenue/INR PAT over FY25-27E. We keep our estimates largely unchanged.

Abhishek Pathak - Research analyst (Abhishek.Pathak@MotilalOswal.com)

Research analysts - Keval Bhagat (Keval.Bhagat@MotilalOswal.com) | Tushar Dhonde (Tushar.Dhonde@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Beat on revenues and margins

- Revenue grew 3.8% QoQ in CC vs. our estimate of 3.7% growth (lower than consensus estimates of 4.2%). New deal TCV stood at USD2.1b (down 5.5% QoQ, up 8.7% YoY) in 3QFY25.
- IT business/ER&D business/P&P grew by 1.5%/5.4%/18.7% QoQ CC.
- EBIT margin was 19.5%, beating our estimate of 19.1%.
- For FY25, revenue growth guidance was upgraded to 4.5%-5.0% YoY in CC (similar for IT Services) from 3.5%-5.0%. EBIT margin guidance was maintained at 18.0-19.0% in FY25.
- PAT was up 8.4% at INR46b (up 5.5% YoY) vs. our est. of INR45b.
- LTM attrition was up 30bp QoQ at 13.2%. Net employee headcount increased 1.0% QoQ in 3QFY25. HCLT added 2,014 freshers (2,932 in 2Q) in this quarter.
- LTM FCF-to-net income stood at 134%.
- HCLT declared an interim dividend of INR18/share, including a special dividend of INR6/share.


Key highlights from the management commentary

- The company anticipates increased technology spending in CY25, driven by transformation and efficiency-related initiatives. Discretionary spending is expected to improve overall.
- Growth in small deals was observed, aligning with client spending patterns. Deals were largely driven by AI transformation projects, with a noticeable reduction in average deal cycles.
- 4Q outlook: A planned reduction in megadeals is expected. Discretionary deal ramp-ups in the telecom sector will taper off in 4Q. Declines are anticipated in the telecom and retail sectors in 4Q, leading to a softer quarter.
- BFSI: The company sees continued momentum in client spending. Al adoption is moving from proof-of-concepts (POCs) to enterprise-level implementations in this vertical. Medium and large-sized deals in platform modernization enabled by Al are being observed in Europe.
- Margin walk: Software business contributed 114bp improvement, while services dropped 22bp.
- Guidance: For FY25, the revenue growth guidance has been upgraded to 4.5%-5.0% YoY cc (including ~50bp contribution from the HPE CTG acquisition, with organic growth at 4.0%-4.5%) from the earlier range of 3.5%-5.0%. Implied organic growth rate for IT Services in 4Q is now 1.6% to 0.6% QoQ. EBIT margin guidance maintained at 18.0%-19.0%.

Valuation and view

We expect HCLT to deliver 18.2% EBIT margin in FY25, which should recover to 18.9% in FY26 as growth improves. We expect HCLT to deliver a CAGR of 7.5%/11.7% in USD revenue/INR PAT over FY25-27E. We keep our estimates largely unchanged. Reiterate **BUY** with a TP of INR2,400 (based on 30x FY27E EPS).


Exhibit 2: For 4Q, implied organic growth for ITB&S to range



Source: MOFSL, Company

Source: MOFSL, Company

Exhibit 3: P&P business posts sub-par YoY growth in 3Q primarily due to delays in renewals



Source: Company, MOFSL

Exhibit 4: All regions clock growth on YoY basis

Geographies (YoY CC Growth, %)	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Americas	10.7	15.0	13.0	17.5	18.2	12.3	10.0	7.3	3.9	6.7	6.8	8.0	7.5
Europe	9.0	12.0	13.6	22.5	21.8	23.3	14.6	10.5	3.9	1.7	5.5	3.0	4.2
ROW	14.9	25.8	15.0	18.2	13.7	11.6	1.4	-6.0	-3.6	-7.5	-7.1	-3.6	-2.6

Source: Company, MOFSL

Exhibit 5: Hi-tech and Telecom showing signs of recovery

Verticals (YoY CC Growth, %)	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Financial Services	13.5	10.2	16.4	15.4	8.8	9.6	14.4	12.5	12.9	12.1	-1.3	-4.5	-1.4
Manufacturing	12.2	16.6	19.1	21.8	21.2	11.8	16.5	3.3	5.8	9.8	3.5	7.1	0.0
Technology & Services	18.1	14.3	34.2	26.6	19.3	17.9	-7.0	-9.5	-9.2	-8.6	2.7	5.6	7.6
Retail & CPG	11.5	6.0	5.8	11.9	-3.8	11.8	3.2	8.1	11.7	8.2	9.7	6.2	17.2
Telecommunications, Media,													
Publishing & Entertainment	12.4	20.2	29.2	27.1	27.9	8.9	-11.7	-10.4	8.3	6.5	69.2	61.2	33.1
Lifesciences & Healthcare	21.3	18.5	15.7	14.4	19.5	1.6	13.4	9.8	0.5	5.4	-4.1	-2.8	-1.1
Public Services#	14.8	7.8	15.2	17.6	16.7	7.6	6.8	1.7	-0.6	0.1	-3.7	-2.0	-4.6

Source: Company, MOFSL

Quartarly parformance

Y/E March		FY24	4			FY25	E		FY24	FY25E	Est.	Var
· -	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QFY25	(%/bp)
Revenue (USD m)	3,200	3,225	3,415	3,430	3,364	3,445	3,533	3,555	13,270	13,897	3,553	-0.6
QoQ (%)	-1.1	0.8	5.9	0.4	-1.9	2.4	2.5	0.6	5.4	4.7	3.1	-60bp
Revenue (INR b)	263	267	284	285	281	289	299	306	1,099	1,174	300	-0.2
YoY (%)	12.1	8.0	6.5	7.1	6.7	8.2	5.1	7.3	8.3	6.8	5.3	-26bp
GPM (%)	35.6	36.2	36.7	35.0	34.5	34.9	35.6	33.7	35.9	34.7	35.0	56bp
SGA (%)	13.6	12.4	11.5	12.0	12.4	11.5	11.3	11.3	12.4	11.6	11.0	27bp
EBITDA	55	59	67	61	58	64	69	64	242	254	68	1.4
EBITDA margin (%)	20.8	22.3	23.5	21.4	20.6	22.1	23.0	21.0	22.0	21.7	22.6	38bp
EBIT	45	49	56	50	48	54	58	53	200	213	57	1.7
EBIT margin (%)	17.0	18.5	19.7	17.6	17.1	18.6	19.5	17.5	18.2	18.2	19.1	38bp
Other income	2	2	3	3	9	3	3	4	9	19	4	-13.5
ETR (%)	24.8	25.3	25.9	24.2	25.4	25.5	25.1	25.0	25.1	25.2	25.5	-42bp
Adjusted PAT	35	38	44	40	43	42	46	43	157	174	45	1.4
QoQ (%)	-11.2	8.4	13.5	-8.4	6.8	-0.5	8.4	-6.7			7.0	145bp
YoY (%)	7.6	9.8	6.2	0.1	20.5	10.5	5.5	7.4	5.7	10.6	4.1	141bp
EPS	13.0	14.1	16.0	14.7	15.7	15.6	16.9	15.8	57.9	63.8	16.7	1.4

Key Performance Indicators

Y/E March		FY2	24			FY25E		FY24
—	1Q	2Q	3Q	4Q	1Q	2Q	3Q	
Revenue (QoQ CC %)	-1.3	1.0	6.0	0.3	-1.6	1.6	3.8	
Costs (% of revenue)								
COGS	64.4	63.8	63.3	65.0	65.5	65.1	64.4	64.1
SGA	13.6	12.4	11.5	12.0	12.4	11.5	11.3	12.4
Margins								
Gross Margin	35.6	36.2	36.7	35.0	34.5	34.9	35.6	35.9
EBIT Margin	17.0	18.5	19.7	17.6	17.1	18.6	19.5	18.2
Net Margin	13.4	14.4	15.3	14.0	15.2	14.7	15.4	14.3
Operating metrics								
Headcount (k)	223	221	225	227	219	219	221	227
Attrition (%)	16.3	14.2	12.8	12.4	12.8	12.9	13.2	12.4
Key Verticals (YoY CC %)								
BFSI	14.4	12.5	12.9	12.1	-1.3	-4.5	-1.4	12.1
Manufacturing	16.5	3.3	5.8	9.8	3.5	7.1	0.0	9.8
Key Geographies (YoY CC %)								
North America	7.3	3.9	6.7	6.8	8.0	7.5	6.2	6.8
Europe	10.5	3.9	1.7	5.5	3.0	4.2	2.6	5.5



Key highlights from the management commentary

Demand and industry outlook

- The company anticipates increased technology spending in CY25, driven by transformation and efficiency-related initiatives. Discretionary spending is expected to improve overall.
- Growth in small deals was observed, aligning with client spending patterns.
 Deals were largely driven by AI transformation projects, with a noticeable reduction in average deal cycles.
- TCV moderated due to shorter-cycle deals, but Annual Contract Value (ACV) grew 23% YoY and 9% QoQ.
- 4Q outlook: A planned reduction in megadeals is expected. Discretionary deal ramp-ups in the telecom sector will taper off in 4Q. The execution of one major project is nearing completion in 3Q. Declines are anticipated in the telecom and retail sectors in 4Q, leading to a softer quarter.
- No ramp-downs of megadeals are expected in FY26. Customer conversations are progressing positively regarding data estate modernization and app modernization.
- BFSI: HCLT sees continued momentum in client spending. Al adoption is moving from POCs to enterprise-level implementations in this vertical. Medium and large-sized deals in platform modernization enabled by Al are being observed in Europe.
- Manufacturing: The weakness in the automotive sector is expected to persist for 1-2 more quarters, while this gives time to construct large transformation deals. Excluding the automotive sector, the vertical shows promising performance, with discretionary spending led by SAP implementations.
- Life Sciences and Healthcare: Discretionary spending has not picked up yet.
- Telecommunications and Media: Growth was partly driven by the HPE CTG acquisition, contributing one month of inorganic growth. Discretionary spending by OEMs remains cautious, but there is focus on network modernization and client experience.
- Retail & CPG: Performance in the US retail sector was strong, driven by the completion of a significant project that contributed double-digit sequential growth. Overall improvement is being observed, and the pipeline looks promising. However, 4Q growth may moderate due to a one-off in this quarter.
- IT business: Organic growth for the services business in 4Q is estimated between -1.3% and 0.6%. Good projects were received in telecom and technology.
- P&P: Delayed renewals from some customers and new onboardings led to subpar YoY growth, with caution expected in renewals in 4Q. SAP business continues to see strong interest due to S4HANA cloud implementation. Full-year growth is expected to be in the low single digits. Margins improved due to reduced costs, lower amortization, and product discontinuation.
- Gen AI: The cost of using large language models (LLMs) has dropped by 85% since 2023, making more use cases viable. Agentic AI presents significant opportunities, especially for cost optimization, and is expected to accelerate the adoption. Customers are increasingly focusing on leveraging AI for legacy modernization.

Margin performance

- EBIT margin stood at 19.5%. FCF conversion on LTM basis was 134%.
- EBIT margin improved by 93bp QoQ from 18.6% in 2QFY25.
- Margin walk: The margin improvement of 93bp QoQ in 3Q included 114bp from software business on account of improved margins in segment, offset by 22bp decline in IT services business.

Other highlights

- The management declared an interim dividend of INR18/share, including a special dividend of INR6/share.
- Cash generation has improved on the back of improved DSO performance. Total DSO, including unbilled, is currently at 77 days, an improvement of two days QoQ and nine days YoY.

Valuation and view

We expect HCLT to deliver 18.2% EBIT margin in FY25, which should recover to 18.9% in FY26 as growth improves. We expect HCLT to deliver a CAGR of 7.5%/11.7% in USD revenue/INR PAT over FY25-27E. We keep our estimates largely unchanged. Reiterate **BUY** with a TP of INR2,400 (based on 30x FY27E EPS).

Exhibit 6: Revised estimates

		Revised			Earlier			Change	
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
USD:INR	84.4	86.0	86.0	84.1	85.0	85.0	0.4%	1.2%	1.2%
Revenue (USD m)	13,897	15,101	16,505	13,926	15,180	16,589	-0.2%	-0.5%	-0.5%
Growth (%)	4.8	9.1	9.3	4.9	9.5	9.3	-10bps	-40bps	0bps
EBIT margin (%)	18.2	18.9	18.8	18.1	18.9	18.8	10bps	0bps	0bps
PAT (INR b)	174	198	219	172	196	216	0.7%	1.2%	1.2%
EPS	63.8	72.7	80.7	63.3	71.9	79.7	0.7%	1.2%	1.3%

Source: MOFSL

Story in charts

Exhibit 7: TCV (new deal wins) at USD2,095m, up by 8.7% YoY; book-to-bill at 0.6x






Exhibit 8: Margin jumps due to strong performance by software business in 3QFY25



Source: Company, MOFSL


Exhibit 10: SG&A expenses currently hovering at its lowest

SG&A expenses (as % of sales)



Source: Company, MOFSL

Exhibit 9: Gross margins improve 70bp QoQ



Source: Company, MOFSL

Exhibit 11: HCLT's valuation premium vs INFO



Source: Bloomberg, MOFSL

Operating metrics

Exhibit 12: Operating metrics

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Service-wise (%)									
IT and Business Services	71.7	73.8	74.7	74.6	71.7	74.4	74.5	74.6	73.0
Engineering and R&D Services	16.6	16.1	15.4	16.0	16.4	16.1	15.9	15.8	16.0
Products and Platform	11.7	10.1	9.9	9.4	11.9	9.5	9.6	9.9	11.3
Vertical-wise (Services) (%)									
BFSI	19.9	21.2	22.6	22.6	21.7	21.6	21.0	20.5	20.3
Manufacturing	18.3	19.0	19.0	19.0	20.1	20.4	19.0	19.5	19.1
Technology and Services	15.4	14.4	14.4	14.4	12.8	12.3	13.0	13.1	13.3
Retail and CPG	8.9	9.0	9.1	9.6	9.6	9.1	9.4	9.6	10.6
Telecom MP&E	9.4	8.8	7.6	8.0	9.7	11.5	12.2	12.1	12.3
Life Sciences	17.1	17.5	17.5	17.5	16.4	16.3	15.9	16.0	15.5
Public Services	10.2	10.2	10.0	9.9	9.7	8.8	9.1	9.2	8.9
Geography-wise (Services) (%)									
US	63.5	63.8	64.5	64.5	64.5	65.2	66.0	65.1	65.5
Europe	29.1	28.9	28.7	28.5	29.0	28.9	27.9	28.4	28.2
RoW	7.4	7.3	6.8	7.0	6.4	5.9	6.1	6.5	6.3
Client-wise (%)									
Top five clients	10.3	10.1	9.8	9.8	9.8	10.4	11.4	12.1	12.6
Top 10 clients	18.2	17.7	17.2	17.2	17.7	18.8	19.6	20.1	20.3
Top 20 clients	28.2	27.8	27.2	27.3	28.0	29.0	30.1	30.8	30.9

Source: Company, MOFSL:

Financials and valuations

Income Statement								(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Sales	707	754	857	1,015	1,099	1,174	1,299	1,419
Change (%)	17.0	6.7	13.6	18.5	8.3	6.8	10.6	9.3
Cost of Goods Sold	453	467	546	662	721	783	848	929
Gross Profit	254	287	311	353	378	391	451	491
Selling & Admin Exp.	87	93	109	127	136	136	159	172
EBITDA	167	193	202	226	242	254	292	318
% of Net Sales	23.6	25.6	23.6	22.3	22.0	21.7	22.5	22.4
Depreciation	28	40	40	41	42	41	47	51
EBIT	139	153	162	185	200	213	245	267
% of Net Sales	19.6	20.4	18.9	18.2	18.2	18.2	18.9	18.8
Other Income	2	7	8	10	9	19	19	25
РВТ	140	160	170	195	210	232	264	292
Тах	29	41	34	46	53	59	66	73
Rate (%)	20.9	25.4	20.3	23.8	25.1	25.2	25.0	25.0
EO Item (net)	0	0	0	0	0	0	0	0
Minority interest	0	1	0	0	0	0	0	0
Adjusted PAT	111	119	135	148	157	174	198	219
Change (%)	9.3	7.4	13.7	9.9	5.7	10.6	14.0	10.5
Balance Sheet								(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Reserves	517	615	620					FIZ/E
Net Worth			020	654	683	674	664	653
	517	615	620	654 654	683 683	674 674		
Loans	517 51	615 39					664	653
Loans Other liabilities			620	654	683	674	664 664	653 653
	51	39	620 39	654 21	683 22	674 22	664 664 22	653 653 22
Other liabilities	51 55	39 55	620 39 43	654 21 45	683 22 66	674 22 68	664 664 22 72	653 653 22 76
Other liabilities Capital Employed	51 55 623	39 55 709	620 39 43 703	654 21 45 720	683 22 66 771	674 22 68 763	664 664 22 72 759	653 653 22 76 751
Other liabilities Capital Employed Gross Block	51 55 623 511	39 55 709 546	620 39 43 703 560	654 21 45 720 596	683 22 66 771 643	674 22 68 763 672	664 664 22 72 759 698	653 653 22 76 751 727
Other liabilities Capital Employed Gross Block Less : Depreciation	51 55 623 511 128	39 55 709 546 168	620 39 43 703 560 208	654 21 45 720 596 249	683 22 66 771 643 291	674 22 68 763 672 332	664 664 22 72 759 698 379	653 653 22 76 751 727 430
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block	51 55 623 511 128 383	39 55 709 546 168 378	620 39 43 703 560 208 352	654 21 45 720 596 249 347	 683 22 66 771 643 291 352 	674 22 68 763 672 332 340	664 664 22 72 759 698 379 319	653 653 22 76 751 727 430 296
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block Other assets	51 55 623 511 128 383 65	39 55 709 546 168 378 69	620 39 43 703 560 208 352 57	654 21 45 720 596 249 347 51	683 22 66 771 643 291 352 52	674 22 68 763 672 332 340 52	664 664 22 72 759 698 379 319 53	653 653 22 76 751 727 430 296 54
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block Other assets Investments	51 55 623 511 128 383 65 105	39 55 709 546 168 378 69 140	620 39 43 703 560 208 352 57 85	654 21 45 720 596 249 347 51 112	683 22 66 771 643 291 352 52 178	674 22 68 763 672 332 340 52 178	664 664 22 72 759 698 379 319 53 178	653 653 22 76 751 727 430 296 54 178
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block Other assets Investments Curr. Assets	51 55 623 511 128 383 65 105 279	39 55 709 546 168 378 69 140 291	620 39 43 703 560 208 352 57 85 397	654 21 45 720 596 249 347 51 112 425	683 22 66 771 643 291 352 52 178 416	674 22 68 763 672 332 340 52 178 436	664 664 22 72 759 698 379 319 53 178 476	653 653 22 76 751 727 430 296 54 178 516
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block Other assets Investments Curr. Assets Debtors	51 55 623 511 128 383 65 105 279 178	39 55 709 546 168 378 69 140 291 175	620 39 43 703 560 208 352 57 85 397 207	654 21 45 720 596 249 347 51 112 425 255	683 22 66 771 643 291 352 52 178 416 255	674 22 68 763 672 332 340 52 178 436 270	664 664 22 72 759 698 379 319 53 178 476 296	653 653 22 76 751 727 430 296 54 178 516 321
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block Other assets Investments Curr. Assets Debtors Cash & Bank Balance	51 55 623 511 128 383 65 105 279 178 38	39 55 709 546 168 378 69 140 291 175 65	620 39 43 703 560 208 352 57 85 397 207 105	654 21 45 720 596 249 347 51 112 425 255 91	683 22 66 771 643 291 352 52 178 416 255 95	674 22 68 763 672 332 340 52 178 436 270 95	664 664 22 72 759 698 379 319 53 178 476 296 102	653 653 22 76 751 727 430 296 54 178 516 321 109
Other liabilities Capital Employed Gross Block Less : Depreciation Net Block Other assets Investments Curr. Assets Debtors Cash & Bank Balance Other Current Assets	51 55 623 511 128 383 65 105 279 178 38 64	39 55 709 546 168 378 69 140 291 175 65 50	620 39 43 703 560 208 352 57 85 397 207 105 85	654 21 45 720 596 249 347 51 112 425 255 91 80	683 22 66 771 643 291 352 52 178 416 255 95 66	674 22 68 763 672 332 340 52 178 436 270 95 71	664 664 22 72 759 698 379 319 53 178 53 178 476 296 102 78	653 653 22 76 751 727 430 296 54 178 516 321 109 85

Financials and valuations

Ratios								
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Diluted (INR)								
EPS	40.7	43.8	49.8	54.8	57.9	63.8	72.7	80.7
Cash EPS	51.2	58.5	64.6	70.1	73.3	78.9	89.9	99.6
Book Value	190.4	226.7	228.6	241.6	252.1	247.5	245.0	240.8
DPS	8.0	26.0	44.0	48.0	48.0	57.4	65.5	72.6
Payout (%)	19.6	59.4	88.3	87.6	82.9	90.0	90.0	90.0
Valuation (x)								
P/E	48.8	45.4	39.9	36.3	34.4	31.2	27.3	24.6
Cash P/E	38.9	34.0	30.8	28.4	27.1	25.2	22.1	20.0
EV/EBITDA	32.4	27.8	26.4	23.5	22.0	21.0	18.2	16.7
EV/Sales	7.7	7.1	6.2	5.2	4.8	4.5	4.1	3.7
Price/Book Value	10.4	8.8	8.7	8.2	7.9	8.0	8.1	8.3
Dividend Yield (%)	0.4	1.3	2.2	2.4	2.4	2.9	3.3	3.7
Profitability Ratios (%)								
RoE	23.6	21.0	21.9	23.3	23.5	25.6	29.6	33.2
RoCE	21.3	18.7	19.6	21.1	21.7	22.8	26.6	29.5
Turnover Ratios								
Debtors (Days)	92	85	88	92	85	84	83	83
Asset Turnover (x)	1.8	2.0	2.4	2.9	3.1	3.5	4.1	4.8
Cash Flow Statement								(INR b)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
CF from Operations	149	166	174	193	201	215	245	270
Chg. in Working Capital	-16	30	-5	-13	23	-2	-5	-4
Net Operating CF	134	196	169	180	224	213	240	266
Net Purchase of FA	-18	-18	-16	-14	-10	-29	-26	-28
Net Purchase of Invest.	-105	-40	30	-25	-57	0	0	0
Net Cash from Inv.	-124	-57	15	-39	-67	-29	-26	-28
Issue of shares/other adj.	0	0	0	0	0	0	0	0
Proceeds from LTB/STB	-15	-79	-31	-29	-14	0	0	0
Dividend Payments	-16	-33	-114	-130	-141	-183	-208	-230
Net CF from Finan.	-32	-112	-145	-159	-154	-183	-208	-230
Free Cash Flow	115	179	153	166	214	184	214	238
Net Cash Flow	-22	27	39	-18	3	1	6	7
Forex difference	0	1	1	4	1	0	0	0
Opening Cash Balance	60	38	66	106	91	95	96	102
Closing Cash Balance	38	66	106	91	95	96	102	110

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating		
Investment Rating	Expected return (over 12-month)	
BUY	>=15%	
SELL	< - 10%	
NEUTRAL	> - 10 % to 15%	
UNDER REVIEW	Rating may undergo a change	
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation	

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on <u>www.motilaloswal.com.</u> MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associates company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e. holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	HCL Technologies
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and

interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No: 022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.